Bull Sessions (8/22/2023)

Pharmaceutical scientist Hugh McManus joins us for a refresher/update on FDA pipeline analysis and some thoughts on Round Table and Tin Cup holding, Regeneron (REGN). These weekly discussions seek to explore relevant topics and/or actionable opportunities for deeper dives. The sessions are generally held on Tuesdays at 2 PM ET. The editorial calendar will include stock analysis methods, specific company studies, portfolio design and management, “missions” within Manifest Investing …

In this August 22, 2023 Bull Sessions webinar, Mark Robertson, Ken Kavula, Kevin Gillogly, and Hugh McManus discuss the current market environment and long-term investment outlook. The speakers cover the recent market volatility in August, using Value Line's low total return forecast as a benchmark for stock analysis. They present research showing that historically, the low total return forecast has been accurate in predicting actual stock returns, with recent years showing it to be slightly conservative—making it a useful cushion for conservative investors. The discussion emphasizes that long-term stock investors face minimal risk of negative returns over 20-30 year horizons, with the S&P 500 experiencing only a handful of negative years over 30 years.

The presentation features extended analysis of the FDA drug pipeline approval process with a specific focus on Regeneron Pharmaceuticals, presented by Hugh McManus from his pharmaceutical industry expertise. The speakers discuss smaller company refinancing needs and interest rate impacts, noting that high-quality smaller companies often carry minimal debt and can manage capital allocation effectively. A recurring theme throughout the session is the importance of humility in investing, illustrated through historical examples of bold market predictions that failed to materialize, including references to Nokia's collapse and incorrect recession forecasts from the 2008-2009 period.

Kevin Gillogly presents findings from the Better Investing community's portfolio tracking dashboard, demonstrating the methodology's effectiveness over recent years. The speakers maintain their focus on quality companies at reasonable prices and long-term, buy-and-hold investing principles, while cautiously noting that August has presented limited opportunities despite recent market weakness.